Judge Explains reason for denying new risperdal trial
Judge Explains Reason for Denying Johnson & Johnson New Risperdal Trial
August 15, 2017
After denying Johnson & Johnson’s request for a new trial concerning abnormal breast development that is allegedly linked to the company’s antipsychotic drug Risperdal, a Pennsylvania state judge has explained that he did so because the pharmaceutical company used “extraordinary” defense strategies that warrant the plaintiff’s search for a new expert witness.
Janssen, the J & J subsidiary that manufactures Risperdal, has appealed the $2.5 million plaintiff decision, had waited an inordinate amount of time, the judge said, before questioning the doctor whom the plaintiffs called as an expert witness. Judge Ramy Djerassi said that he would have permitted the motion had it been filed before the trial commenced.
The trial found that Risperdal was responsible for Austin Piedger’s gynecomastia, a condition in which the young boy grew breasts like those of an adult woman. He had taken Risperdal for five years to treat behavioral symptoms associated with autism.
In 2002, when Piedger began taking Risperdal, the drug had received approval from the U.S. Food and Drug Administration (FDA) only for the treatment of adults. It was not until 2006 that Risperdal’s labeling was altered to include a warning about gynecomastia.
Janssen has vowed to continue to appeal the verdict.
If you or a loved one has suffered from serious side effects related to Risperdal, you should consult your doctor right away. After you’ve done that, contact the offices of TheLawFirm.com so we can begin the process of filing your lawsuit.
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:
Real lawyers, real results!
no recovery, no fee!